Cargando…
Simultaneous integrated boost therapy of carcinoma of the hypopharynx/larynx with and without flattening filter - a treatment planning and dosimetry study
BACKGROUND: The aim of this study was to investigate if the flattening filter free (FFF) irradiation mode of a linear accelerator (linac) is advantageous as compared to the flat beam (FF) irradiation mode in intensity modulated radiation therapy (IMRT) and volumetric modulated arc therapy (VMAT) for...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5499025/ https://www.ncbi.nlm.nih.gov/pubmed/28679448 http://dx.doi.org/10.1186/s13014-017-0850-8 |
_version_ | 1783248397295157248 |
---|---|
author | Dobler, Barbara Obermeier, Tina Hautmann, Matthias G. Khemissi, Amine Koelbl, Oliver |
author_facet | Dobler, Barbara Obermeier, Tina Hautmann, Matthias G. Khemissi, Amine Koelbl, Oliver |
author_sort | Dobler, Barbara |
collection | PubMed |
description | BACKGROUND: The aim of this study was to investigate if the flattening filter free (FFF) irradiation mode of a linear accelerator (linac) is advantageous as compared to the flat beam (FF) irradiation mode in intensity modulated radiation therapy (IMRT) and volumetric modulated arc therapy (VMAT) for carcinoma of the hypopharynx / larynx. METHODS: Four treatment plans were created for each of 10 patients for an Elekta Synergy linac with Agility collimating device, a dual arc VMAT and a nine field step and shoot IMRT each with and without flattening filter. Plan quality was compared considering target coverage and dose to the organs at risk. All plans were verified by a 2D–ionization-chamber-array and delivery times were compared. Peripheral point doses were determined as a measure of second cancer risk. The Wilcoxon test was used for statistical analysis with a significance level of 0.05. RESULTS: Plan quality was similar for all four treatment plans without statistically significant differences of clinical relevance. The clinical goals were met in all plans for the PTV-SIB (V(95%) > 95%), the spinal cord (D(1ccm) < 45 Gy) and the brain stem (D(1ccm) < 48 Gy). For the parotids, the goal of D(50%) < 30 Gy was met in 70% and 60% of the plans for the left and right parotid respectively, and the V(95%) of the SIB reached an average of 94%. Delivery times were similar for FF and FFF and significantly decreased by around 70% for VMAT as compared to IMRT. Peripheral doses were significantly reduced by 18% in FFF mode as compared to FF and by 26% for VMAT as compared to IMRT. Lowest peripheral doses were found for VMAT FFF, followed by VMAT FF. CONCLUSIONS: The FFF mode of a linear accelerator is advantageous for the treatment of hypopharynx/larynx carcinoma only with respect to reduction of second cancer induction in peripheral organs for the combination of Elekta Synergy linacs and Oncentra® External Beam v4.5 treatment planning system. This might be of interest in a therapy with curative intent. |
format | Online Article Text |
id | pubmed-5499025 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-54990252017-07-10 Simultaneous integrated boost therapy of carcinoma of the hypopharynx/larynx with and without flattening filter - a treatment planning and dosimetry study Dobler, Barbara Obermeier, Tina Hautmann, Matthias G. Khemissi, Amine Koelbl, Oliver Radiat Oncol Research BACKGROUND: The aim of this study was to investigate if the flattening filter free (FFF) irradiation mode of a linear accelerator (linac) is advantageous as compared to the flat beam (FF) irradiation mode in intensity modulated radiation therapy (IMRT) and volumetric modulated arc therapy (VMAT) for carcinoma of the hypopharynx / larynx. METHODS: Four treatment plans were created for each of 10 patients for an Elekta Synergy linac with Agility collimating device, a dual arc VMAT and a nine field step and shoot IMRT each with and without flattening filter. Plan quality was compared considering target coverage and dose to the organs at risk. All plans were verified by a 2D–ionization-chamber-array and delivery times were compared. Peripheral point doses were determined as a measure of second cancer risk. The Wilcoxon test was used for statistical analysis with a significance level of 0.05. RESULTS: Plan quality was similar for all four treatment plans without statistically significant differences of clinical relevance. The clinical goals were met in all plans for the PTV-SIB (V(95%) > 95%), the spinal cord (D(1ccm) < 45 Gy) and the brain stem (D(1ccm) < 48 Gy). For the parotids, the goal of D(50%) < 30 Gy was met in 70% and 60% of the plans for the left and right parotid respectively, and the V(95%) of the SIB reached an average of 94%. Delivery times were similar for FF and FFF and significantly decreased by around 70% for VMAT as compared to IMRT. Peripheral doses were significantly reduced by 18% in FFF mode as compared to FF and by 26% for VMAT as compared to IMRT. Lowest peripheral doses were found for VMAT FFF, followed by VMAT FF. CONCLUSIONS: The FFF mode of a linear accelerator is advantageous for the treatment of hypopharynx/larynx carcinoma only with respect to reduction of second cancer induction in peripheral organs for the combination of Elekta Synergy linacs and Oncentra® External Beam v4.5 treatment planning system. This might be of interest in a therapy with curative intent. BioMed Central 2017-07-05 /pmc/articles/PMC5499025/ /pubmed/28679448 http://dx.doi.org/10.1186/s13014-017-0850-8 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Dobler, Barbara Obermeier, Tina Hautmann, Matthias G. Khemissi, Amine Koelbl, Oliver Simultaneous integrated boost therapy of carcinoma of the hypopharynx/larynx with and without flattening filter - a treatment planning and dosimetry study |
title | Simultaneous integrated boost therapy of carcinoma of the hypopharynx/larynx with and without flattening filter - a treatment planning and dosimetry study |
title_full | Simultaneous integrated boost therapy of carcinoma of the hypopharynx/larynx with and without flattening filter - a treatment planning and dosimetry study |
title_fullStr | Simultaneous integrated boost therapy of carcinoma of the hypopharynx/larynx with and without flattening filter - a treatment planning and dosimetry study |
title_full_unstemmed | Simultaneous integrated boost therapy of carcinoma of the hypopharynx/larynx with and without flattening filter - a treatment planning and dosimetry study |
title_short | Simultaneous integrated boost therapy of carcinoma of the hypopharynx/larynx with and without flattening filter - a treatment planning and dosimetry study |
title_sort | simultaneous integrated boost therapy of carcinoma of the hypopharynx/larynx with and without flattening filter - a treatment planning and dosimetry study |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5499025/ https://www.ncbi.nlm.nih.gov/pubmed/28679448 http://dx.doi.org/10.1186/s13014-017-0850-8 |
work_keys_str_mv | AT doblerbarbara simultaneousintegratedboosttherapyofcarcinomaofthehypopharynxlarynxwithandwithoutflatteningfilteratreatmentplanninganddosimetrystudy AT obermeiertina simultaneousintegratedboosttherapyofcarcinomaofthehypopharynxlarynxwithandwithoutflatteningfilteratreatmentplanninganddosimetrystudy AT hautmannmatthiasg simultaneousintegratedboosttherapyofcarcinomaofthehypopharynxlarynxwithandwithoutflatteningfilteratreatmentplanninganddosimetrystudy AT khemissiamine simultaneousintegratedboosttherapyofcarcinomaofthehypopharynxlarynxwithandwithoutflatteningfilteratreatmentplanninganddosimetrystudy AT koelbloliver simultaneousintegratedboosttherapyofcarcinomaofthehypopharynxlarynxwithandwithoutflatteningfilteratreatmentplanninganddosimetrystudy |